Novel Therapeutic Strategy in the Treatment of Diabetes Type 2, the Use of Autologous Peripheral Blood Stem Cells in 15 Patients: Is There Any Relation with the Incretin-GLP-1/GIP Axis?

Ciro Gargiulo *

Faculty of Medicine, HMIC-Tan Tao University, Ho Chi Minh City, Vietnam

Van H. Pham

Faculty of Medicine, Nam Khoa Bioteck-Tan Tao University, Ho Chi Minh City, Vietnam

Tao D. Huynh

Department of Stem Cell Research, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam

Vo L. H. Trieu

Faculty of Medicine, HMIC-Tan Tao University, Ho Chi Minh City, Vietnam

Nguyen C. D. Kieu

Faculty of Medicine, HMIC-Tan Tao University, Ho Chi Minh City, Vietnam

Melvin Shiffman

Plastic Surgeon and Stem Cell Specialist Private Consultant, Tustin, CA, USA

Mark J. Holterman

Faculty of Surgery, UICOMP, Chicago, IL, USA

Sergey K. Aityan

Multidisciplinary Research Center, Lincoln University, Oakland, CA, USA

Luis Filgueira

Department of Medicine, Faculty of Anatomy University of Fribourg, Fribourg, Switzerland

*Author to whom correspondence should be addressed.


Abstract

Peripheral blood stem cells (PB-SCs) are probably the most common and the most “slighted” stem cells utilized in medicine, their clinical application is back to year 1986 with the intent of replacing BM as a stem-cell source. This brief manuscript provides a general view into the amazing world of PB-SCs. Since then PB-SCs have been widely studied and the outcomes revealed a very particular biological character that lead to their clinical use in degenerative metabolic diseases as diabetes type 2 (DM2). Based on published data, we have proposed that a combination of both low glycemic index diet (LGI diet) and PB-SCs would generate major improvements in glucose metabolism via positive modification on GLP-1/GIP-Insulin axis. We have elucidated the beneficial effects of the LGI diet combined with PB-SCs on glucose tolerance in 15 individuals. We examined physiologic changes in whole-body insulin sensitivity and insulin and lipid profile after autologous PB-SCs, followed by a LGI diet regimen, which is a central tool in glucose clearance in the post-treatment period. Thus, it was discussed the modulating and regenerative activity of PB-SCs and LGI diet on the insulin, incretin/GLP-1 axis in response to sugar drive typical of DM2 condition.

Keywords: HPB-SCs, LGI diet, type 2DM, HbA1c, MSCs, NSCs, ESCs, HSCs, GLP-1, incretin, insulin


How to Cite

Gargiulo, Ciro, Van H. Pham, Tao D. Huynh, Vo L. H. Trieu, Nguyen C. D. Kieu, Melvin Shiffman, Mark J. Holterman, Sergey K. Aityan, and Luis Filgueira. 2017. “Novel Therapeutic Strategy in the Treatment of Diabetes Type 2, the Use of Autologous Peripheral Blood Stem Cells in 15 Patients: Is There Any Relation With the Incretin-GLP-1 GIP Axis?”. Journal of Advances in Medicine and Medical Research 20 (7):1-16. https://doi.org/10.9734/BJMMR/2017/32206.

Downloads

Download data is not yet available.